Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method.

Eur J Pharm Sci. 1999 Aug;8(4):269-81. Unique Identifier : AIDSLINE MED/99356107
Wulff M; Alden M; Department of Pharmaceutical Chemistry, Physical and Inorganic; Chemistry, Box 574, Biomedical Center, Uppsala University, S-751; 23, Uppsala, Sweden.

Abstract: The melting method was investigated as a possible method for producing drug-cyclodextrin (CD) inclusion compounds in a carrier. Various solid dispersions of alpha-, beta- and gamma-CD in polyethylene glycol (PEG) 6000 with and without the addition of 5% w/w indomethacin or griseofulvin were prepared using the original components. Characterisations of the samples included X-ray powder diffraction, modulated-temperature differential scanning calorimetry and dissolution tests by the paddle method according to USP XXI standard. Evidence of a complex between indomethacin and beta-CD in PEG 6000 was found. An indomethacin-gamma-CD complex formed a well defined phase in the PEG carrier, with tetragonal structure and unit cell parameters a=23.885(35) A and c=23.181(64) A. No complexation of indomethacin with alpha-CD, or with griseofulvin and beta-CD could be detected. It is suggested that competition between PEG and the drug for the binding to different CDs along with varying patterns of water loss from the CDs influence the inclusion reaction. The formation of complexes was accompanied by a decrease in the relative crystallinity of the dispersions. Dissolution tests showed that the CDs have a delaying effect on the release of indomethacin from PEG 6000 in the order alpha-CD<gamma-CD</=beta-CD.

Keywords: JOURNAL ARTICLE Anti-Inflammatory Agents, Non-Steroidal/*CHEMISTRY Antibiotics, Antifungal/*CHEMISTRY Calorimetry, Differential Scanning Chemistry, Pharmaceutical/METHODS Crystallization Cyclodextrins/*CHEMISTRY Delayed-Action Preparations Drug Carriers/CHEMISTRY Griseofulvin/*CHEMISTRY Indomethacin/*CHEMISTRY Pharmaceutic Aids/*CHEMISTRY Polyethylene Glycols/*CHEMISTRY Solubility Support, Non-U.S. Gov't X-Ray Diffraction $KWDgov'tx-raydiffraction$
991230
A99C0989

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .